| London Stock Exchange: CRX
Cyprotex Plc provides pharmaceutical research and development services. The company operates as a contract research organization that specializes in ADME Tox, which is the analysis of the absorption, distribution, metabolism, excretion, and toxicity properties of drugs, cosmetics and agrochemicals; mechanistic toxicology and high content toxicology screening services; and predictive modeling using PBPK and QSAR techniques, including Cloe PK for in vivo PK prediction. It serves drug-discovery organizations, pharmaceutical companies, and not-for-profit laboratories. The company also supports the research efforts of the cosmetic and agrochemical industries, principally for in vitro toxicity testing. Cyprotex was founded in April 1999 and is headquartered in Macclesfield, United Kingdom.